Navigation Links
Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel® at World Pain Congress in Montreal, Canada
Date:9/2/2010

ng tissues where the drug exerts its well-known anti-inflammatory and analgesic effects. The Company intends to leverage its Transdel™ platform technology to expand and create a portfolio of topical products for a variety of indications.  The Company is actively pursuing partnerships with companies to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical products.  For more information, please visit http://www.transdelpharma.com.

Safe Harbor Statement

The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the Company's interpretation of the results of its Phase 3 clinical trial for Ketotransdel®; the Company's ability to obtain regulatory approval to market Ketotransdel; and the Company's ability to complete additional development activities for products utilizing its proprietary transdermal delivery platform. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the FDA may not agree with the Company's interpretation of the results of the Phase 3 clinical trial for Ketotransdel or may challenge the adequacy of the Company's clinical trial design or the execution of the clinical trial; the FDA may require the Company to complete additional clinical trials for Ketotransdel® before the Company can submit a 505(b)(2) NDA application; the results of any future clinical trials may not be favorable and the Company may never receive regulatory approval for Ketotransdel®; and the Company's current need to raise additional funding to complete its product development and clinical trial plans. More detailed information about the Company and the risk fact
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Transdel Pharmaceuticals Announces Management Reorganization
2. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
3. Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
4. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
5. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
6. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
8. Pfizer to Acquire FoldRx Pharmaceuticals
9. Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China
10. Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015
11. Webcast Alert: Isis Pharmaceuticals Hosts Expert Panel Conference Call to Discuss Mipomersen Data Presented at the ESC Congress 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... -- The North American spine surgery devices market is ... U.S. having the maximum market share. This region is ... The market, by product type, encompasses spinal ... devices, non-fusion implant devices, and spine bone stimulators devices. ... is the largest and fastest-growing segment. Key players ...
(Date:6/3/2015)...  Actavis plc (NYSE: ACT ), a leading global ... and President of Actavis, will provide an overview and update ... Global Healthcare Conference in Rancho Palos Verdes, Calif. ... The presentation will take place on Wednesday, June ... Resort, Rancho Palos Verdes, Calif.  To ...
(Date:6/3/2015)... , June 02, 2015 Research ... addition of the "The Future of Pharmaceutical ... As they are in a desperate need to ... low cost, drug companies have been increasingly utilizing ... their productivity while constantly streamlining their internal operation. ...
Breaking Medicine Technology:Actavis to Present at the Goldman Sachs 36th Annual Global Healthcare Conference 2The Future of Pharmaceutical Outsourcing: 2015 Report 2
... MOUNTAIN VIEW, Calif. , Jan. 28 Omnicell, Inc. (Nasdaq: ... facilities, today announced results for its fourth quarter and year ended ... fourth quarter of 2009 was $54.7 million , up $0.7 ... $7.4 million or 11.9% from the fourth quarter of 2008. ...
... , SAN DIEGO , Jan. 28 ... Phase II clinical trial evaluating CTS-1027 in combination with pegylated ... activity, safety and tolerability of the triple combination will be ... is a significant unmet medical need in HCV patients who ...
Cached Medicine Technology:Omnicell Announces Fourth Quarter and Full-Year 2009 Results 2Omnicell Announces Fourth Quarter and Full-Year 2009 Results 3Omnicell Announces Fourth Quarter and Full-Year 2009 Results 4Omnicell Announces Fourth Quarter and Full-Year 2009 Results 5Omnicell Announces Fourth Quarter and Full-Year 2009 Results 6Omnicell Announces Fourth Quarter and Full-Year 2009 Results 7Omnicell Announces Fourth Quarter and Full-Year 2009 Results 8Omnicell Announces Fourth Quarter and Full-Year 2009 Results 9Omnicell Announces Fourth Quarter and Full-Year 2009 Results 10Omnicell Announces Fourth Quarter and Full-Year 2009 Results 11Omnicell Announces Fourth Quarter and Full-Year 2009 Results 12Omnicell Announces Fourth Quarter and Full-Year 2009 Results 13Omnicell Announces Fourth Quarter and Full-Year 2009 Results 14Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 2Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 3
(Date:6/3/2015)... Accountable care organizations (ACOs) are increasingly partnering ... worries that these product types were too similar to ... that product-based ACOs will continue to grow in size ... June issue of Atlantic Information Services, Inc.’s (AIS) AIS’s ... that the backlash from HMOs seems to be fading ...
(Date:6/3/2015)... Save On Medical ( http://www.saveonmedical.com ) ... shopping for health care procedures easier for patients on ... look and makes it easier to compare the prices ... , Now, when patients search for the procedure they ... they can see the provider’s price and Docometer quality ...
(Date:6/3/2015)... The National Resident Matching Program Board of Directors ... of Medical Education at the University of California, San Diego ... , “It is an honor to assume the ... Dr. Savoia. “NRMP’s goal is to provide a fair, ... programs, and I welcome the opportunity to guide the organization ...
(Date:6/3/2015)... 2015 Dr. Steven Reisman, a nationally recognized ... ( http://www.newyorkcardiac.com ) located in NYC, announced today the expansion ... practice. In most cases, depending on the level of care ... call, they will be seen by a cardiologist that same ... cardiologist is to ensure that people who have an urgent ...
(Date:6/3/2015)... DC (PRWEB) June 03, 2015 A ... will be honored with a Global Inspire Award at ... recognizes the organization’s outstanding volunteers for their leadership, level ... scale. , The recipients of the Author(s) ... group of authors whose article has made a significant ...
Breaking Medicine News(10 mins):Health News:Product-Based ACOs Are Poised for Growth, Industry Observers Tell AIS Newsletter 2Health News:Product-Based ACOs Are Poised for Growth, Industry Observers Tell AIS Newsletter 3Health News:Save On Medical Launches New Mobile-Optimized Website 2Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 2Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 3Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 4Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4
... as eunuchs, can now choose a gender of their liking ... //to a special procedure developed at the All India Institute ... 1,100 patients have already given proper gender identities as males ... life, doctors at the premier research and referral institute said. ...
... looking at lactate with a much more positive eye, ... in the immediate //hours after a traumatic brain injury ... right, it could change how emergency room physicians and ... the first critical hours after injury. ,Previous ...
... technology that can quickly screen all 20,000-plus human genes for ... affect how sensitive human cancer cells are to certain chemotherapy ... in the April 12 edition of the journal Nature, researchers ... library of small RNA molecules – the first used by ...
... With allergy season in full bloom, the American Academy of ... of what you can do to cope with the pollen ... specialist can help. // ,This spring, pollen from blooming ... 45 million Americans, causing itching eyes, sneezing, nasal stuffiness, nasal ...
... in erectile dysfunction, decreased libido, anemia, sarcopenia, memory loss, ... ,While a low serum testosterone level is well-known for ... overall physical functioning and fall risk has not been ... of the Archives of Internal Medicine, Orwoll and colleagues ...
... of Queensland men have never been screened for prostate, colorectal ... ,Screening for colorectal cancer currently has stronger scientific evidence for ... skin cancer, but a new study in the Medical Journal ... colorectal cancer test than the other two. ...
Cached Medicine News:Health News:New Procedure Paves Way for Eunuchs to Choose a Gender and Conceive 2Health News:Study Challenges Conventional Treatment of Traumatic Brain Injury 2Health News:Gene Screening Points Way to More Effective Chemotherapy 2Health News:April Showers Bring May Flowers – And Plenty of Pollen, To 2Health News:Low Serum Testosterone Levels Associated With Fall Risk in Elderly Men 2
... IgG Test is an ELISA ... of IgG to Varicella Zoster ... used as,an aid to determine ... status may be determined using ...
The ImmunoWELL Thyroglobulin IgG Quantitative Test is a quantitative enzyme immunoassay (EIA) for screening and detection of autoantibodies against human thyroglobulin in serum and is used as an aid ...
... Screening Panel 4 is an enzyme ... detection of autoantibodies against various specific ... and Sm) in serum, and is ... diagnosis of systemic lupus erythematosus (SLE), ...
The 920M PLUS handheld pulseoximeter provides on-the-spot bloodoximetry and heart rate readings....
Medicine Products: